Company intelligence / Profile preview

MOON-X

Ownership: Private
Development stage: Other

Overview

Moon (Guangzhou) Biotech has established the world's largest and most biodiverse microbial strain library and genetic component library with over 260,000–270,000 strains. The company leverages these resources along with advanced synthetic biology to develop bio-based products for agriculture, biomedicine, and protein sectors. No clinical trial results are reported as the focus is on platform technologies and industrial applications rather than direct therapeutic candidates.

Therapeutic areas: OtherInfectious Diseases
Modalities: Microbial-based productsSynthetic biology platforms
Industry: Non-Drug Biotech

Partnerships

SDIC Juli Investment Management Co., Ltd. (strategic investor)

Beyond the preview

Go deeper on MOON-X.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MOON-X.

Explore the full profile